Health
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia – The Lancet
The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile
and induced strong humoral and cellular immune responses in participants. Further
investigation is needed of the effectiveness of this vaccine for prevention of COVID-19.

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions…
-
Business24 hours ago
Is Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
Noosa News10 hours ago
Commissioner thanks police officer who threw a speed radar at a car
-
General24 hours ago
Taiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts
-
Noosa News18 hours ago
Countdown on for Noosa Eat & Drink Festival 2025